Sugi Predict

Sugi Predict / Compounds / SCHEMBL25199084

SCHEMBL25199084

SCHEMBL25199084

O=Cc1cc(-c2cccnc2F)n(S(=O)(=O)c2ccc(F)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH3A1 P30838 1/20 0.39
▸ NFE2L2 Q16236 4/20 0.37
▸ LMNA P02545 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ HSD11B1 P28845 1/20 0.35
▸ COMT P21964 1/20 0.35
▸ GRM4 Q14833 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ ELAVL1 Q15717 1/20 0.34
▸ HDAC3 O15379 2/20 0.34
▸ HDAC4 P56524 2/20 0.34
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC7 Q8WUI4 2/20 0.34
▸ HDAC2 Q92769 2/20 0.34
▸ HDAC10 Q969S8 2/20 0.34
▸ HDAC11 Q96DB2 2/20 0.34
▸ HDAC8 Q9BY41 2/20 0.34
▸ HDAC6 Q9UBN7 2/20 0.34
▸ HDAC9 Q9UKV0 2/20 0.34
▸ HDAC5 Q9UQL6 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31019963 1.00 ALDH3A1 (0.39) ALDH3A1NFE2L2LMNAKDM4EHSD11B1
SCHEMBL1278538 0.92 MET (0.40) HSD11B1HDAC3HDAC4HDAC1HDAC7
SCHEMBL31019965 0.91 PKM (0.44) ALDH3A1NFE2L2KDM4EHSD11B1GRM4
SCHEMBL25194047 0.91 PKM (0.44) ALDH3A1NFE2L2KDM4EHSD11B1GRM4
SCHEMBL30339778 0.84 HTR6 (0.39) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29265326 0.84 HTR6 (0.39) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2411295 0.84 MET (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL25189646 0.84 HTR6 (0.41) ALDH3A1LMNAKDM4EGAAELAVL1
SCHEMBL2409482 0.83 PKM (0.41) —
SCHEMBL2409997 0.83 NFE2L2 (0.38) NFE2L2KDM4EHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051275-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT HANA PHARM CO., LTD. (KR) 2025-02-13 — — US disclosed
EP-4434966-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT Hana Pharm. Co. Ltd. (KR) 2024-09-25 — — EP disclosed
WO-2023090942-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT 하나제약 주식회사 2023-05-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051275-A1 PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT STOM, SI, PGC ALDH3A1 1806/4885NFE2L2 2098/4885LMNA 4778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.